Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data

BACKGROUND: Migraine is a debilitating neurological disorder that affects 14.1% of the US and 14.7% of the European populations. Chronic migraine (CM) is broadly defined as headache occurring on ≥15 days per month for ≥3 months, and has an estimated worldwide prevalence of 1.4% to 2.2%. Onabotulinum...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Brendan, Gaul, Charly, Martelletti, Paolo, García-Moncó, Juan Carlos, Brown, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587510/
https://www.ncbi.nlm.nih.gov/pubmed/28879545
http://dx.doi.org/10.1186/s10194-017-0802-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587510/
https://www.ncbi.nlm.nih.gov/pubmed/28879545
http://dx.doi.org/10.1186/s10194-017-0802-6

Ejemplares similares